| __timestamp | Intra-Cellular Therapies, Inc. | TG Therapeutics, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 10337679 | 24518692 |
| Thursday, January 1, 2015 | 18187286 | 19886580 |
| Friday, January 1, 2016 | 24758063 | 12631689 |
| Sunday, January 1, 2017 | 23666957 | 21977998 |
| Monday, January 1, 2018 | 30099855 | 20759000 |
| Tuesday, January 1, 2019 | 64947625 | 20838000 |
| Wednesday, January 1, 2020 | 186363444 | 121812000 |
| Friday, January 1, 2021 | 272611040 | 152137000 |
| Saturday, January 1, 2022 | 358782000 | 83231000 |
| Sunday, January 1, 2023 | 409864000 | 122706000 |
Unleashing the power of data
In the competitive world of biotechnology, strategic spending on Selling, General, and Administrative (SG&A) expenses can be a key differentiator. Over the past decade, Intra-Cellular Therapies, Inc. and TG Therapeutics, Inc. have demonstrated distinct spending patterns. From 2014 to 2023, Intra-Cellular Therapies increased its SG&A expenses by nearly 3,900%, peaking in 2023. This aggressive investment reflects their commitment to expanding market presence and operational capabilities. In contrast, TG Therapeutics exhibited a more conservative growth of approximately 400% in the same period, with a notable spike in 2021. This divergence highlights differing strategic priorities: while Intra-Cellular Therapies focuses on rapid expansion, TG Therapeutics appears to prioritize steady, sustainable growth. These patterns offer valuable insights into each company's market strategy and potential future trajectories.
Comparing SG&A Expenses: Amgen Inc. vs TG Therapeutics, Inc. Trends and Insights
Cost Management Insights: SG&A Expenses for Zoetis Inc. and Intra-Cellular Therapies, Inc.
Breaking Down SG&A Expenses: Zoetis Inc. vs TG Therapeutics, Inc.
Intra-Cellular Therapies, Inc. vs Sarepta Therapeutics, Inc.: SG&A Expense Trends
Cost Management Insights: SG&A Expenses for Intra-Cellular Therapies, Inc. and Alkermes plc
Intra-Cellular Therapies, Inc. and Amicus Therapeutics, Inc.: SG&A Spending Patterns Compared
Intra-Cellular Therapies, Inc. or CRISPR Therapeutics AG: Who Manages SG&A Costs Better?
Breaking Down SG&A Expenses: Summit Therapeutics Inc. vs TG Therapeutics, Inc.
Cost Management Insights: SG&A Expenses for Exelixis, Inc. and TG Therapeutics, Inc.
Breaking Down SG&A Expenses: Grifols, S.A. vs TG Therapeutics, Inc.
Who Optimizes SG&A Costs Better? Cytokinetics, Incorporated or TG Therapeutics, Inc.
SG&A Efficiency Analysis: Comparing TG Therapeutics, Inc. and Veracyte, Inc.